Share on StockTwits

WuXi PharmaTech (NYSE:WX) posted its quarterly earnings results on Wednesday. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.02, AR Network reports. The company had revenue of $163.40 million for the quarter, compared to the consensus estimate of $162.11 million.

WuXi PharmaTech (NYSE:WX) traded up 1.13% on Wednesday, hitting $32.21. The stock had a trading volume of 577,138 shares. WuXi PharmaTech has a one year low of $23.48 and a one year high of $40.72. The stock has a 50-day moving average of $32.63 and a 200-day moving average of $34.6. The company has a market cap of $2.301 billion and a P/E ratio of 20.98.

WX has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of WuXi PharmaTech from an “underperform” rating to a “neutral” rating in a research note on Wednesday, July 16th. They now have a $33.50 price target on the stock. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of WuXi PharmaTech in a research note on Thursday, May 15th. They now have a $45.00 price target on the stock. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. WuXi PharmaTech presently has an average rating of “Buy” and an average price target of $37.90.

WuXi PharmaTech (NYSE:WX) Inc, (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in People’s Republic of China and the United States.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.